{"id":"NCT02219932","sponsor":"Biogen","briefTitle":"Efficacy and Safety Study of Prolonged-Release Fampridine in Participants With Multiple Sclerosis","officialTitle":"A Multicenter, Randomized, Double Blind, Placebo Controlled Study to Assess the Long-Term Efficacy and Safety of Prolonged Release Fampridine (BIIB041) 10 mg, Administered Twice Daily in Subjects With Multiple Sclerosis (ENHANCE)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2014-09","primaryCompletion":"2016-02","completion":"2016-02","firstPosted":"2014-08-19","resultsPosted":"2017-03-27","lastUpdate":"2017-03-27"},"enrollment":646,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Multiple Sclerosis"],"interventions":[{"type":"DRUG","name":"fampridine","otherNames":["dalfampridine","Ampyra","Fampyra","fampridine prolonged-release tablets","BIIB041"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Fampridine 10 mg BID","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The primary objective is to determine whether prolonged-release fampridine (10 mg twice daily) has a clinically meaningful effect on participant-reported walking ability over a 24-week study period.\n\nThe secondary objectives are: to determine whether prolonged-release fampridine 10 mg taken twice daily (BID) has a clinically meaningful effect on dynamic and static balance, physical impact of multiple sclerosis (MS), and upper extremity function over a 24-week study period; to evaluate criteria for early assessment of response to fampridine that can predict clinically meaningful benefits in walking ability and balance; to assess the safety and tolerability of prolonged-release fampridine 10 mg twice daily over a 24-week treatment period.","primaryOutcome":{"measure":"Proportion of Participants Achieving a Mean Improvement of â‰¥ 8 Points From Baseline on the Multiple Sclerosis Walking Scale (MSWS-12) Over 24 Weeks","timeFrame":"Baseline to 24 weeks","effectByArm":[{"arm":"Placebo","deltaMin":0.336,"sd":null},{"arm":"Fampridine 10 mg BID","deltaMin":0.432,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.006"},{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG001","p":null}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":7},"locations":{"siteCount":87,"countries":["United States","Bulgaria","Czechia","Finland","Italy","Lithuania","Netherlands","Poland","Russia","Serbia","United Kingdom"]},"refs":{"pmids":["30535670"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":21,"n":319},"commonTop":["Urinary tract infection","Multiple sclerosis relapse","Fall","Nasopharyngitis","Back pain"]}}